コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 meric genes and with phenotypic overlap with hypertrophic cardiomyopathy.
2 myosin inhibitor, in symptomatic obstructive hypertrophic cardiomyopathy.
3 iomyopathy, and 2 were found to be end-stage hypertrophic cardiomyopathy.
4 aluated its prognostic role in patients with hypertrophic cardiomyopathy.
5 nt of Fabry disease mimicking nonobstructive hypertrophic cardiomyopathy.
6 s support a cumulative variant hypothesis in hypertrophic cardiomyopathy.
7 red with suspicion of genetically determined hypertrophic cardiomyopathy.
8 t of routine evaluation of all patients with hypertrophic cardiomyopathy.
9 anxiety-like behavior in an animal model of hypertrophic cardiomyopathy.
10 in successfully prevented the development of hypertrophic cardiomyopathy.
11 anisotropy effectively discriminate CA from hypertrophic cardiomyopathy.
12 bstitution in Sco1, which in humans causes a hypertrophic cardiomyopathy.
13 ostic value of GLS and LAVI in patients with hypertrophic cardiomyopathy.
14 nical management and genetic architecture of hypertrophic cardiomyopathy.
15 es risk factors that are unique to pediatric hypertrophic cardiomyopathy.
16 duced MEE at the early and advanced stage of hypertrophic cardiomyopathy.
17 ng improves exercise capacity in adults with hypertrophic cardiomyopathy.
18 achycardia, congenital long QT syndrome, and hypertrophic cardiomyopathy.
19 ficiency causes Danon's disease, an X-linked hypertrophic cardiomyopathy.
20 gulated in dilated cardiomyopathy but not in hypertrophic cardiomyopathy.
21 er phenotypes, including 1,078 patients with hypertrophic cardiomyopathy.
22 ice developed a cardiac phenotype similar to hypertrophic cardiomyopathy.
23 tonia, optic atrophy, axonal neuropathy, and hypertrophic cardiomyopathy.
24 f cardiac disease, such as arrhythmogenic or hypertrophic cardiomyopathy.
25 MI), patients undergoing septal ablation for hypertrophic cardiomyopathy.
26 eta-adrenergic signaling, heart failure, and hypertrophic cardiomyopathy.
27 f MF in 30 transplanted hearts of end-stage, hypertrophic cardiomyopathy.
28 lcohol septal ablation (ASA) in patient with hypertrophic cardiomyopathy.
29 Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy.
30 mpaction, and 2 fourth-degree relatives with hypertrophic cardiomyopathy.
31 therapeutic strategy to treat NS-associated hypertrophic cardiomyopathy.
32 d health status in patients with obstructive hypertrophic cardiomyopathy.
33 in C), are the most common cause of familial hypertrophic cardiomyopathy.
34 for preventing sudden death in patients with hypertrophic cardiomyopathy.
35 displaying skeletal myopathy with late-onset hypertrophic cardiomyopathy.
36 mechanism of a mutation that causes familial hypertrophic cardiomyopathy.
37 or pulmonary arterial hypertension, 0.91 for hypertrophic cardiomyopathy, 0.86 for cardiac amyloid, a
43 FD had T2 elevation (FD 58.2+/-5.0 ms versus hypertrophic cardiomyopathy 55.6+/-4.3 ms, chronic myoca
44 agnosed with dilated cardiomyopathy, 246 had hypertrophic cardiomyopathy, 61 had alcohol/drug-induced
45 diography was performed in 427 patients with hypertrophic cardiomyopathy (66% men, age 52+/-15 years)
47 ients undergoing septal alcohol ablation for hypertrophic cardiomyopathy, a human model of planned my
48 ted with shortened survival in patients with hypertrophic cardiomyopathy across all three cohorts, an
51 fficiency represents a target for therapy in hypertrophic cardiomyopathy although therapeutic benefit
53 LGE presence and its extent in patients with hypertrophic cardiomyopathy and a low-intermediate 5-yea
55 ry hypertension in patients with obstructive hypertrophic cardiomyopathy and advanced heart failure.
56 t (LGE) is an important prognostic marker in hypertrophic cardiomyopathy and an extent >15% it is ass
57 n I (TNNI3) gene mutations account for 3% of hypertrophic cardiomyopathy and carriers have a heteroge
60 n Mendelian forms of these diseases, such as hypertrophic cardiomyopathy and long-QT syndrome, uncove
61 ciated with adverse outcome in patients with hypertrophic cardiomyopathy and may help to optimize ris
62 tions reflect the complex pathophysiology of hypertrophic cardiomyopathy and may provide clues for th
64 tive athletes, two deaths were attributed to hypertrophic cardiomyopathy and none to arrhythmogenic r
65 sults showed the animal suffered from feline hypertrophic cardiomyopathy and severe pulmonary edema a
66 d Gaa(c.1826dupA) murine model recapitulates hypertrophic cardiomyopathy and skeletal muscle weakness
67 at have previously been considered causal in hypertrophic cardiomyopathy and that are overrepresented
68 conversions associated with fatal infantile hypertrophic cardiomyopathy and the neurological disorde
69 cardiomyopathy, 1.09 (95% CI, 1.06-1.12) for hypertrophic cardiomyopathy, and 1.10 (1.06-1.13) for al
70 rformed at diastole and systole in 20 CA, 11 hypertrophic cardiomyopathy, and 10 control subjects wit
71 ith aortic stenosis and associated secondary hypertrophic cardiomyopathy, and 15 controls) in identic
72 y is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of
73 inergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, and other hereditary cardia
77 gests that double mutations in patients with hypertrophic cardiomyopathy are not rare and are associa
79 autosomal recessive form of NS with massive hypertrophic cardiomyopathy as clinically the most preva
80 nder fasting conditions.Sirt5KO mice develop hypertrophic cardiomyopathy, as evident from the increas
81 importance of this finding in patients with hypertrophic cardiomyopathy, as well as the long-term sa
85 ion to accelerated aging, these mice develop hypertrophic cardiomyopathy at ~13 months of age, presum
86 sidase A gene variants are misinterpreted as hypertrophic cardiomyopathy because of the lack of extra
87 function not only in participants with overt hypertrophic cardiomyopathy, but also in carriers of sar
88 n thin-filament proteins have been linked to hypertrophic cardiomyopathy, but it has never been demon
89 e following septal myectomy in patients with hypertrophic cardiomyopathy, but their incidence and eff
90 nd disease (pulmonary arterial hypertension, hypertrophic cardiomyopathy, cardiac amyloid, and mitral
91 ure of cardiomyopathies, with an emphasis on hypertrophic cardiomyopathy caused by sarcomeric mutatio
94 ce in SHaRe most frequently occurred because hypertrophic cardiomyopathy centers had access to differ
95 Discordance in variant classification among hypertrophic cardiomyopathy centers is largely attributa
96 ment may be achieved by: 1) confining ASA to hypertrophic cardiomyopathy centers of excellence with h
100 tating heart conditions, notably dilated and hypertrophic cardiomyopathies (CMs), are associated with
101 BPC3 variants and relatively small genotyped hypertrophic cardiomyopathy cohorts have precluded detai
102 iotensin II receptor blockers in preclinical hypertrophic cardiomyopathy-eg, in genotype-positive but
104 heart transplantation (HT) in patients with hypertrophic cardiomyopathy evaluated at 2 Italian refer
105 n in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) explored the safety and eff
106 d >3 times and accounted for 78 of 185 (42%) hypertrophic cardiomyopathy families with a causal varia
108 Consecutive patients treated with ASA for hypertrophic cardiomyopathy from 2003 to 2019 at a terti
109 ed from surgical explants from patients with hypertrophic cardiomyopathy, from a transaortic-constric
110 ic cardiomyopathy who had undergone targeted hypertrophic cardiomyopathy genetic testing (either mult
112 ucture Many recommendations from the earlier hypertrophic cardiomyopathy guidelines have been updated
113 more than a decade, risk stratification for hypertrophic cardiomyopathy has been enhanced by targete
114 t of drug-refractory symptoms of obstructive hypertrophic cardiomyopathy has long been debated and is
116 alcohol septal ablation (ASA) in obstructive hypertrophic cardiomyopathy have been limited to small,
118 ses: long QT syndrome (LQTS) (n = 48 [42%]), hypertrophic cardiomyopathy (HCM) (n = 28 [24%]), Brugad
121 in clinical practice, in particular, between hypertrophic cardiomyopathy (HCM) and increased LV wall
123 verely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM) and mild septal hypert
124 ferential strain) in a genotyped cohort with hypertrophic cardiomyopathy (HCM) and to explore correla
125 pathogenic mutations in the TNT1 region, six hypertrophic cardiomyopathy (HCM) and two dilated cardio
128 tests and a case cohort of individuals with hypertrophic cardiomyopathy (HCM) based on comprehensive
129 tein C) founder mutations account for 35% of hypertrophic cardiomyopathy (HCM) cases in the Netherlan
130 terations in autophagy have been reported in hypertrophic cardiomyopathy (HCM) caused by Danon diseas
131 etic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarcomere pr
133 graphic data for automated discrimination of hypertrophic cardiomyopathy (HCM) from physiological hyp
137 Over the last 50 years, the epidemiology of hypertrophic cardiomyopathy (HCM) has changed because of
138 he impact of sex on phenotypic expression in hypertrophic cardiomyopathy (HCM) has not been well char
139 amine the contribution of MYBPC3(Delta25) to hypertrophic cardiomyopathy (HCM) in a large patient coh
168 specific clinical red flags in patients with hypertrophic cardiomyopathy (HCM) older than 25 years.
169 A previously under-recognized subset of hypertrophic cardiomyopathy (HCM) patients with left ven
172 prospective registry of 2,755 patients with hypertrophic cardiomyopathy (HCM) recruited from 44 site
173 h genetic mutations that are associated with hypertrophic cardiomyopathy (HCM) remains challenging.
175 eric gene mutation carriers with early-stage hypertrophic cardiomyopathy (HCM) to test whether valsar
176 with severe heart failure due to obstructive hypertrophic cardiomyopathy (HCM) who are at unacceptabl
177 e term "end stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular
178 5% for dilated cardiomyopathy (DCM), 6% for hypertrophic cardiomyopathy (HCM), 12% for restrictive c
179 c myosin heavy chain gene (MYH7) can lead to hypertrophic cardiomyopathy (HCM), a heritable disease c
180 hickness such as cardiac amyloidosis, septal hypertrophic cardiomyopathy (HCM), and apical HCM exhibi
181 ures in noncompaction cardiomyopathy (NCCM), hypertrophic cardiomyopathy (HCM), and dilated cardiomyo
182 for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachy
183 e autosomal dominant phenocopy of sarcomeric hypertrophic cardiomyopathy (HCM), characterized by vent
184 AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of produci
185 the time of greatest risk for patients with hypertrophic cardiomyopathy (HCM), largely because of th
188 omeric mutation, which is exhibited in human hypertrophic cardiomyopathy (HCM), to investigate the in
189 ns, such as dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which are often due t
204 rker for outcome prediction in patients with hypertrophic cardiomyopathy (HCM); however, its clinical
205 this case the two major clinical phenotypes (hypertrophic cardiomyopathy, HCM and dilated cardiomyopa
206 issense variants in JPH2 have been linked to hypertrophic cardiomyopathy; however, pathogenic "loss o
208 lts, clinicians routinely assess the risk of hypertrophic cardiomyopathy in a patient's relatives and
209 rithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patie
210 rithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patie
212 rn pathological and clinical descriptions of hypertrophic cardiomyopathy in the 1950s, which focused
213 e of multiple rare variants in patients with hypertrophic cardiomyopathy in the setting of comprehens
214 e show several pathophysiological insults in hypertrophic cardiomyopathy, including the R403Q myosin
215 atients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8+/-3.4 year
220 g exercise recommendations for patients with hypertrophic cardiomyopathy is challenging because of co
221 tricular tachycardia (NSVT) in patients with hypertrophic cardiomyopathy is incompletely resolved.
222 for additional genes that are implicated in hypertrophic cardiomyopathy is initiated on an affected
225 The most common single genetic cause of hypertrophic cardiomyopathy is the recurrent MYBPC3 (myo
226 cardial strain are reported in patients with hypertrophic cardiomyopathy, ischemic heart disease, dia
227 ercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) trial, the lar
228 y, phenotype-positive patients with isolated hypertrophic cardiomyopathy <18 years of age at diagnosi
229 sis light chain [AL] type), 40 patients with hypertrophic cardiomyopathy matched for demographics and
230 n in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy [MAVERICK-HCM]; NCT03442764)
231 scle, suggesting that MYL2 mutated models of hypertrophic cardiomyopathy may be useful research tools
232 ND One-hundred and ninety-five patients with hypertrophic cardiomyopathy (median age, 52.8+/-15.1 yea
234 is preliminary study involving patients with hypertrophic cardiomyopathy, moderate-intensity exercise
236 ular cardiomyopathy (n = 111), DCM (n = 95), hypertrophic cardiomyopathy (n = 40) and peripartum card
237 2), occult myocardial infarction (n=13), and hypertrophic cardiomyopathy (n=9) were most frequent.
239 diac death (SCD) in athletes is debated with hypertrophic cardiomyopathy often reported as the most c
242 e underlying sarcomere hypercontractility of hypertrophic cardiomyopathy, one of the most prevalent h
245 thic pulmonary fibrosis, systemic sclerosis, hypertrophic cardiomyopathy, or myelofibrosis from Stanf
248 We generated maps of regulatory elements on hypertrophic cardiomyopathy patients (ChIP-seq N=14 and
249 rentially active regulatory elements between hypertrophic cardiomyopathy patients and controls can of
250 rs of genes differentially regulated between hypertrophic cardiomyopathy patients and controls showed
252 iameter, volume, and strain to risk stratify hypertrophic cardiomyopathy patients for new-onset atria
253 outcomes of medically refractory obstructive hypertrophic cardiomyopathy patients undergoing alcohol
256 onary hypertension was common in obstructive hypertrophic cardiomyopathy patients with advanced heart
257 of measured cardiopulmonary hemodynamics in hypertrophic cardiomyopathy patients with heart failure,
258 ith similar EF in 20 control subjects and 20 hypertrophic cardiomyopathy patients with increased wall
259 op of LA diameter to predict new-onset AF in hypertrophic cardiomyopathy patients with LA diameter <4
260 The study cohort comprises 217 consecutive hypertrophic cardiomyopathy patients with primary preven
264 C mutant, we sought to determine whether the hypertrophic cardiomyopathy phenotype observed in papill
265 ogenic mechanisms that drive severe clinical hypertrophic cardiomyopathy phenotypes and for identifyi
267 g was performed on 358 consecutive genotyped hypertrophic cardiomyopathy probands at 5 tertiary hyper
269 nding protein C ( MYBPC3) gene, which causes hypertrophic cardiomyopathy, recapitulated seminal disea
274 Icelandic patients clinically diagnosed with hypertrophic cardiomyopathy resulted in identification o
277 naire-Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopathy Symptom Questionnaire Shortn
278 uating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy) targeted young sarcomeric g
279 markedly lower among centers specialized in hypertrophic cardiomyopathy than among clinical laborato
280 ation (ASA) for the treatment of obstructive hypertrophic cardiomyopathy, the arrhythmogenicity of th
281 l fibrosis (MF) has clinical implications in hypertrophic cardiomyopathy, the extent, type, and distr
282 inding for the sarcomere variants that cause hypertrophic cardiomyopathy, the titin and sarcomere var
283 ate a SCD risk prediction model in pediatric hypertrophic cardiomyopathy to guide SCD prevention stra
284 explain the responsiveness of patients with hypertrophic cardiomyopathy to verapamil in managing lef
285 dically refractory patients with obstructive hypertrophic cardiomyopathy treated according to the Ame
286 d clinical trial involving 136 patients with hypertrophic cardiomyopathy was conducted between April
287 l hypertrophy, traditionally associated with hypertrophic cardiomyopathy, was the commonest pattern o
288 genic (LP/P; >/=2) variants in patients with hypertrophic cardiomyopathy were described 10 years ago
291 d older) with obstructive or non-obstructive hypertrophic cardiomyopathy were randomly assigned via c
292 ferences between MYH7- and MYBPC3-associated hypertrophic cardiomyopathy when assessed by cardiac mag
293 microvasculature's role in diseases such as hypertrophic cardiomyopathy where misalignment of cardio
294 ently affected with typical manifestation of hypertrophic cardiomyopathy, which can progress to heart
296 outcomes of 2,482 patients with obstructive hypertrophic cardiomyopathy who underwent transaortic se
297 10 (20%) heterozygous family members showed hypertrophic cardiomyopathy with an atypical distributio
298 cular centres in 13 countries, patients with hypertrophic cardiomyopathy with an LVOT gradient of 50
299 effect in South Lebanon and causes malignant hypertrophic cardiomyopathy with early SCD even in the a
300 cardiac magnetic resonance imaging revealed hypertrophic cardiomyopathy with left ventricular dysfun